Dash Bio Featured Articles

1. Building Bioanalysis Infrastructure For Modern Drug Development 10/20/2025

   Drug development accelerates with AI, decentralized trials, and adaptive protocols, but legacy CRO infrastructure lags. Platform-based systems enable speed, quality, automation, and continuous improvement.

2. 5 Outdated Practices Holding Back Modern Bioanalysis 10/20/2025

   Bioanalysis must replace outdated paper, manual processes, and disjointed systems with integrated, automated platforms for continuous validation, efficiency, compliance, and to support complex modern therapies.

3. Built Like A Tech Company: Why CROs Need A New Operating System 10/20/2025

   See why building digital, automated infrastructure is essential, and better aligns CROs with today's speed, compliance, and innovation needs.

4. Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO 9/2/2025

   In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional; it is essential to survival and success.

5. Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows 9/2/2025

   Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.

6. Why Bioanalysis Needs To Break Free From Manual Bottlenecks 9/2/2025

   Bioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.